Algert Global LLC Purchases 62,570 Shares of Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Algert Global LLC has increased its position in Agios Pharmaceuticals by 511.2% during the 1st quarter, now owning 74,810 shares valued at approximately $2.19 million.
• Agios Pharmaceuticals CEO Brian Goff sold 18,700 shares at an average price of $33.54, leading to a 15.07% decrease in his ownership.
• Several analysts have adjusted their price targets for Agios Pharmaceuticals, with Scotiabank lowering theirs from $71.00 to $65.00 while maintaining a "sector outperform" rating.

Algert Global LLC boosted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 511.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 74,810 shares of the biopharmaceutical company's stock after purchasing an additional 62,570 shares during the period. Algert Global LLC owned about 0.13% of Agios Pharmaceuticals worth $2,192,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. PNC Financial Services Group Inc. increased its holdings in Agios Pharmaceuticals by 16.2% in the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 499 shares during the period. Gallagher Fiduciary Advisors LLC increased its holdings in Agios Pharmaceuticals by 7.6% in the fourth quarter. Gallagher Fiduciary Advisors LLC now owns 11,110 shares of the biopharmaceutical company's stock valued at $365,000 after purchasing an additional 788 shares during the period. Envestnet Asset Management Inc. grew its holdings in Agios Pharmaceuticals by 3.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock worth $815,000 after acquiring an additional 795 shares during the period. XTX Topco Ltd raised its position in shares of Agios Pharmaceuticals by 11.3% in the 4th quarter. XTX Topco Ltd now owns 9,272 shares of the biopharmaceutical company's stock worth $305,000 after acquiring an additional 943 shares in the last quarter. Finally, CWM LLC raised its position in shares of Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 996 shares in the last quarter.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 11,914 shares of Agios Pharmaceuticals stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $37.99, for a total transaction of $452,612.86. Following the completion of the transaction, the insider owned 61,271 shares in the company, valued at approximately $2,327,685.29. The trade was a 16.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tsveta Milanova sold 2,770 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $92,905.80. Following the transaction, the insider directly owned 26,122 shares in the company, valued at approximately $876,131.88. This represents a 9.59% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 57,448 shares of company stock worth $2,026,141. 4.30% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO traded up $0.81 during trading on Wednesday, reaching $39.27. 725,149 shares of the stock were exchanged, compared to its average volume of 976,397. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58. The stock has a fifty day moving average of $37.00 and a two-hundred day moving average of $32.98. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of 3.57 and a beta of 0.80.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%.The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. Sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Scotiabank dropped their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research note on Monday, July 28th. Bank of America dropped their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Finally, Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $56.33.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.